Use of complement C5-inhibitor eculizumab in patients with infection-associated hemolytic uremic syndrome – a case-series report
Open Access
- 11 March 2025
- journal article
- case report
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-11
Abstract
Background: Hemolytic uremic syndrome (HUS), characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury (AKI), remains a leading cause of pediatric AKI. The complement system has a crucial role in the pathogenesis of atypical hemolytic uremic syndrome (aHUS) and eculizumab (ECZ) was approved as standard of care for its treatment. The two widely characterized forms of infection-associated HUS are Shiga toxin-producing E. coli (STEC)-HUS and Streptococcus pneumoniae-associated (SP)-HUS. Extrarenal manifestations such as central nervous system (CNS) involvement occur approximately in 20% of the cases and are accompanied by higher mortality. Abnormalities of the alternative complement pathway may also contribute to the development of both STEC-HUS and SP-HUS, offering a potential treatment option for complement C5 inhibition. Beyond best supportive care as standard therapeutic approach, ECZ has been successfully used in both STEC-HUS and SP-HUS patients. We provide further support that early use of ECZ for infection-associated HUS with severe clinical manifestation and abnormal complement-activation profile may be an effective therapeutic approach. Case presentation: We report on three children (median age: 2 years, range: 2–10 years) diagnosed with infection-associated HUS treated with complement C5-inhibitor ECZ. All three patients were treated with ECZ and had excellent outcome. We retrospectively analyzed the clinical course, laboratory data and outcome of children with infection-associated HUS treated with ECZ. Conclusion: In accordance with previous observations ECZ is an efficacious therapeutic choice in severe HUS patients with multiorgan involvement. A detailed complement activation profile, especially sC5b-9, is useful to indicate ECZ administration.Keywords
All Related Versions
Funding Information
- University of Debrecen
This publication has 42 references indexed in Scilit:
- Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvementPediatric Nephrology, 2023
- Eculizumab use in patients with pneumococcal-associated hemolytic uremic syndrome and kidney outcomesPediatric Nephrology, 2023
- Neurological involvement in children with hemolytic uremic syndromeEuropean Journal of Pediatrics, 2021
- Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndromePediatric Nephrology, 2021
- New insights into the pathogenesis of Streptococcus pneumoniae–associated hemolytic uremic syndromePediatric Nephrology, 2019
- Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidencePediatric Blood & Cancer, 2019
- Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndromePediatric Nephrology, 2018
- Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective studyPediatric Nephrology, 2018
- Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidenceEuropean Journal of Pediatrics, 2017
- Streptococcus pneumoniae-associated hemolytic uremic syndromePediatric Nephrology, 2008